Abstract
Objective: To reveal the cutoff point and influencing factors in the dynamic change in phenotypic group in patients with stable angina pectoris (SAP) after Xinxuekang capsule treatment.
Methods: Five hundred and seventy-six SAP patients were randomly assigned to receive Xinxuekang (XXK) capsules or Compound Danshen (CDS) tablets for 8 weeks. Global similarity degree analysis and nonlinear mixed effects modeling (NONMEM) were employed to reveal the cutoff points and influencing factors in dynamic changes in the SAP phenotypic group. The phenotypic group was defined as the six phenotypes in SAP, including angina, choking sensation in the chest, palpitations, dark purple lips, ecchymosis on the tongue, and fine-choppy pulse, which were quantitatively evaluated on Days 0, 14, 28, 42, and 56.
Results: Variation in the six individual phenotypes and distribution of the SAP phenotypic profile were similar between the two experimental groups, but cutoff points for changes in the SAP phenotypic group were 7.28 and 10.73 weeks in XXK and CDS groups, respectively. Degree of severity of SAP as well as study site significantly affected the tendency for change in the SAP Xueyu Zheng in both XXK and CDS treatment groups. Different Chinese patent drugs affected the tendency for change in phenotypic group in patients with SAP. XXK was superior to CDS in controlling a clinical phenotypic group.
Conclusion: Based on global similarity degree analysis and NONMEM, the cutoff point and influencing factors in phenomic variation of SAP may be determined, to improve the development and modification of treatment regimens.
Keywords: Stable angina pectoris, similarity degree analysis, nonlinear mixed effect model, treatment effectiveness.
Current Vascular Pharmacology
Title:Dynamic Changes in Phenotypic Groups in Patients with Stable Angina Pectoris after Treatment with Xinxuekang Capsule: A Randomized Controlled Trial
Volume: 13 Issue: 4
Author(s): Guo-Xin Li, Yong-Yan Wang, Chun-Ti Shen, Zhong Wang, Lei Zhang, Qi-guang Chen, Song-Shan Liu, Shu-Rong Liu, Zhuo-Ming Li, Xiao-Feng Wang, Jie Xue, Dong-Hai Wang, Bo Dong, Li-Ying Wang, Xi-Yan Yang, Xiang-Ling Liu, Si-Yuan Hu, Zhi-Wei Jing, Li-Ya Su, Hong-Li Wu, Bi-Wei Chen, Ya-Nan Yu, Wei Lu, Jun Liu and Jian-Yuan Tang
Affiliation:
Keywords: Stable angina pectoris, similarity degree analysis, nonlinear mixed effect model, treatment effectiveness.
Abstract: Objective: To reveal the cutoff point and influencing factors in the dynamic change in phenotypic group in patients with stable angina pectoris (SAP) after Xinxuekang capsule treatment.
Methods: Five hundred and seventy-six SAP patients were randomly assigned to receive Xinxuekang (XXK) capsules or Compound Danshen (CDS) tablets for 8 weeks. Global similarity degree analysis and nonlinear mixed effects modeling (NONMEM) were employed to reveal the cutoff points and influencing factors in dynamic changes in the SAP phenotypic group. The phenotypic group was defined as the six phenotypes in SAP, including angina, choking sensation in the chest, palpitations, dark purple lips, ecchymosis on the tongue, and fine-choppy pulse, which were quantitatively evaluated on Days 0, 14, 28, 42, and 56.
Results: Variation in the six individual phenotypes and distribution of the SAP phenotypic profile were similar between the two experimental groups, but cutoff points for changes in the SAP phenotypic group were 7.28 and 10.73 weeks in XXK and CDS groups, respectively. Degree of severity of SAP as well as study site significantly affected the tendency for change in the SAP Xueyu Zheng in both XXK and CDS treatment groups. Different Chinese patent drugs affected the tendency for change in phenotypic group in patients with SAP. XXK was superior to CDS in controlling a clinical phenotypic group.
Conclusion: Based on global similarity degree analysis and NONMEM, the cutoff point and influencing factors in phenomic variation of SAP may be determined, to improve the development and modification of treatment regimens.
Export Options
About this article
Cite this article as:
Li Guo-Xin, Wang Yong-Yan, Shen Chun-Ti, Wang Zhong, Zhang Lei, Chen Qi-guang, Liu Song-Shan, Liu Shu-Rong, Li Zhuo-Ming, Wang Xiao-Feng, Xue Jie, Wang Dong-Hai, Dong Bo, Wang Li-Ying, Yang Xi-Yan, Liu Xiang-Ling, Hu Si-Yuan, Jing Zhi-Wei, Su Li-Ya, Wu Hong-Li, Chen Bi-Wei, Yu Ya-Nan, Lu Wei, Liu Jun and Tang Jian-Yuan, Dynamic Changes in Phenotypic Groups in Patients with Stable Angina Pectoris after Treatment with Xinxuekang Capsule: A Randomized Controlled Trial, Current Vascular Pharmacology 2015; 13 (4) . https://dx.doi.org/10.2174/1570161112666141014151858
DOI https://dx.doi.org/10.2174/1570161112666141014151858 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Natural and Synthetic Agents Targeting Inflammation and Angiogenesis for Chemoprevention of Prostate Cancer
Current Cancer Drug Targets Does Non-Alcoholic Fatty Liver Disease (NAFLD) Increase Cardiovascular Risk?
Endocrine, Metabolic & Immune Disorders - Drug Targets The First Approved Agent in the Glitazar’s Class: Saroglitazar
Current Drug Targets Blood Pressure and the Risk of Dementia: A Dose-Response Meta-Analysis of Prospective Studies
Current Neurovascular Research Endothelial (Dys)Function in Lone Atrial Fibrillation
Current Pharmaceutical Design The Effect of Antihypertensive Drugs on Central Blood Pressure Beyond Peripheral Blood Pressure. Part II: Evidence for Specific Class-Effects of Antihypertensive Drugs on Pressure Amplification
Current Pharmaceutical Design Analysis of Current Antifungal Agents and Their Targets within the Pneumocystis carinii Genome
Current Drug Targets Diabetes, the Renin-Angiotensin System and Heart Disease
Current Vascular Pharmacology Impact of Polypharmacy on Adherence to Evidence-Based Medication in Patients who Underwent Percutaneous Coronary Intervention
Current Vascular Pharmacology Redox Homeostasis, Bioactive Agents and Transduction Therapy
Current Signal Transduction Therapy Ischemic Strokes in Congenital Bleeding Disorders: Comparison with Myocardial Infarction and other Acute Coronary Syndromes
Cardiovascular & Hematological Disorders-Drug Targets The Coronary Circulation in Arterial Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) HIV Infection, Antiretroviral Therapy Initiation and Longitudinal Changes in Biomarkers of Organ Function
Current HIV Research There is no Failure, Only Discovery—the Year Ahead for CARving New Paths
Current Alzheimer Research Prevalence of Obesity, Hypertension, Diabetes, and Metabolic Syndrome and Its Cardiovascular Complications
Current Hypertension Reviews Ventilation/Perfusion SPECT - A New Challenge for Detection of Pulmonary Embolism. Can Multi Detector Computed Tomography Replace Lung Scintigraphy?
Current Medical Imaging EDITORIAL: Validation Techniques for Therapeutic Molecules in Drug Discovery
Current Topics in Medicinal Chemistry Bedtime Hypertension Chronotherapy: Concepts and Patient Outcomes
Current Pharmaceutical Design The Impact of Cardiovascular Diseases on Cardiovascular Regulation During Exercise in Humans: Studies on Metaboreflex Activation Elicited by the Post-exercise Muscle Ischemia Method
Current Cardiology Reviews Effects of Ranolazine on Cardiovascular System
Recent Patents on Cardiovascular Drug Discovery